Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

04-1570-I

Sigma-Aldrich

Anti-RNA polymerase II subunit B1 (phospho-CTD Ser-7) Antibody, clone 4E12

culture supernatant, clone 4E12, from rat

Sinónimos:

DNA-directed RNA polymerase II subunit RPB1, RNA polymerase II subunit B1, DNA-directed RNA polymerase II subunit A, DNA-directed RNA polymerase III largest subunit, RNA-directed RNA polymerase II subunit RPB1

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Código UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41

origen biológico

rat

Nivel de calidad

forma del anticuerpo

culture supernatant

tipo de anticuerpo

primary antibodies

clon

4E12, monoclonal

reactividad de especies

mouse

reactividad de especies (predicha por homología)

human (based on 100% sequence homology)

técnicas

ChIP: suitable
ELISA: suitable
western blot: suitable

isotipo

IgG1κ

Nº de acceso NCBI

Nº de acceso UniProt

Condiciones de envío

wet ice

modificación del objetivo postraduccional

phosphorylation (pSer7)

Información sobre el gen

human ... POLR2B(5431)

Descripción general

RPB1 (RNA polymerase II subunit B1) is the catalytic component of RNA polymerase II which synthesizes mRNA and non-coding RNAs. During transcription, elongation is influenced by the phosphorylation status of the C-terminal domain (CTD) of RPB1, which acts as an assembly platform for factors regulating transcription initiation, elongation, termination and mRNA processing. Phosphorylation occurs mainly at residues ′Ser-2′ and ′Ser-5′ of the tandem 7 residue repeats in the C-terminal domain (CTD), which activates Pol II. This phosphorylation also can occur at ′Ser-7′ of the heptapepdtide repeat. This antibody recognizes the ′Ser-7′ CTD residue of RPB1.

Especificidad

Demonstrated to react with human RBP1 in Ni et al., 2011. Transcription 2:5, 237-242
This antibody recognizes RNA polymerase II subunit B1 phosphorylated at Ser7 of the C-terminal domain (CTD).

Inmunógeno

Epitope: Phosphorylated Ser7 of the C-terminal domain (CTD)
Ovalbumin-conjugated linear peptide corresponding to human RNA polymerase II subunit B1 phosphorylated at Ser7 of the C-terminal domain (CTD).

Aplicación

Anti-RNA polymerase II subunit B1 (phospho-CTD Ser-7) Antibody, clone 4E12 is a highly specific rat monoclonal antibody & that targets RNA Polymerase & has been tested in western blotting.
Chromatin Immunoprecipitation Analysis: A representative lot was used by an independent laboratory to immunoprecipitate RNA polymerase II subunit B1 (phospho-CTD Ser-5) in ChIP (Chapman, R., et al. (2007). Science. 318(5857):1780-1782.).
Demonstrated to react with human RBP1 in Ni et al., 2011. Transcription 2:5, 237-242

Calidad

Evaluated by Western Blotting in untreated and lambda phosphatase treated NIH/3T3 cell lysate.

Western Blotting Analysis: A 1:2,000 dilution from a representative lot detected RNA polymerase II subunit B1 (phospho-CTD Ser-7) in 10 μg of untreated NIH/3T3 cell lysate.

Descripción de destino

~220 kDa observed

Ligadura / enlace

Replaces: 04-1570

Forma física

Rat monoclonal IgG1κ with 0.05% sodium azide.

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Código de clase de almacenamiento

10 - Combustible liquids

Clase de riesgo para el agua (WGK)

WGK 1


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Emily Brookes et al.
Cell stem cell, 10(2), 157-170 (2012-02-07)
Polycomb repressor complexes (PRCs) are important chromatin modifiers fundamentally implicated in pluripotency and cancer. Polycomb silencing in embryonic stem cells (ESCs) can be accompanied by active chromatin and primed RNA polymerase II (RNAPII), but the relationship between PRCs and RNAPII
Jing Gao et al.
Haematologica (2021-06-25)
Despite significant progress in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), prognosis of patients with relapsed disease remains poor due to the emergence of drug resistance and subsequent disease progression. Identification of
Tanaz Sharifnia et al.
Nature medicine, 25(2), 292-300 (2019-01-22)
Chordoma is a primary bone cancer with no approved therapy1. The identification of therapeutic targets in this disease has been challenging due to the infrequent occurrence of clinically actionable somatic mutations in chordoma tumors2,3. Here we describe the discovery of
Xiaohong Zhao et al.
Cell reports, 34(11), 108870-108870 (2021-03-18)
Ibrutinib, a bruton's tyrosine kinase (BTK) inhibitor, provokes robust clinical responses in aggressive mantle cell lymphoma (MCL), yet many patients relapse with lethal Ibrutinib-resistant (IR) disease. Here, using genomic, chemical proteomic, and drug screen profiling, we report that enhancer remodeling-mediated
Jiajun Zhang et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(11), 2681-2692 (2020-01-16)
Malignancy of cancer cells depends on the active transcription of tumor-associated genes. Recently, unique clusters of transcriptional enhancers, termed super-enhancers, have been reported to drive the expression of genes that define cell identity. In this study, we characterized specific super-enhancer-associated

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico